UDP-Glucuronosyltransferases: Structure, Isoforms, and Substrates
UGT (UDP-glucuronosyltransferases; UGT1A/UGT2A/UGT2B gene families; ER membrane (lumenal active site; type I single-pass TM protein; C-terminal anchor)); catalytic reaction: UDP-glucuronic acid (UDPGA; 4-MU-β-D-glucuronide equivalent; donor) + substrate-OH/NH2/COOH/SH → substrate-O-glucuronide (glucuronic acid β-glycosidic bond) + UDP; net: hydrophobic substrate → hydrophilic glucuronide → MRP2/ABCC2 export (bile) or MRP3 (blood → kidney → UGT2B7/UGT1A9 renal re-glucuronidation) → urine; key isoforms: UGT1A1 (HUB1; the bilirubin glucuronidase; also oestradiol (E2-3-G); SN-38 (active irinotecan metabolite) → SN-38-G (inactive); UGT1A1*28 (Gilbert’s syndrome; TA7 TATA box → reduced UGT1A1 expression ~70% → unconjugated hyperbilirubinaemia; generally benign; SN-38 toxicity ↑); Nrf2/ARE + AhR targets); UGT1A3 (bile acids; lipophilic xenobiotics; CDCA/LCA glucuronidation; Nrf2/ARE); UGT1A4 (amines; tertiary amines → quaternary glucuronides; lamotrigine/imipramine); UGT1A6 (simple phenols; serotonin; aspirin → salicylic acid-glucuronide); UGT1A9 (propofol; mycophenolic acid; NSAID glucuronidation); UGT2B7 (morphine-6-glucuronide (active); carbamazepine-10,11-trans-diol; fatty acids; hyodeoxycholic acid; opioid glucuronidation); UGT2B15 (androgens; dihydrotestosterone-3αG; 3α-androstanediol-G); UGT2B17 (testosterone → testosterone-17βG; DHEA → DHEA-G; high expression in prostate; AhR/Nrf2 regulated); UDPGA biosynthesis: glucose-1-phosphate + UTP → UDPG (UDP-glucose pyrophosphorylase; UGP2) → UDPG + 2NAD+ → UDPGA (UDP-glucose dehydrogenase; UGDH; 2 NADH produced); UGDH substrate UDP-Glc from glycolysis-UTP; Mg2+ cofactor for UGP2.
Spirulina Mechanisms in UGT Glucuronidation
Nrf2/ARE-Driven UGT1A1 and UGT2B7 Upregulation
UGT1A1 (bilirubin glucuronidase; ARE at −1185/−1175 (UGT1A1 promoter; Nrf2 ChIP-confirmed; activated by sulforaphane/tBHQ/keap1-knockout → UGT1A1 +50–150% in mouse models; human HepG2: Nrf2 activators → UGT1A1 +25–50%); also AhR (aryl hydrocarbon receptor; XRE/DRE in UGT1A1 promoter −290/−280; AhR activation → UGT1A1 +2–4× in intestinal cells; hepatic AhR less responsive); C/EBPα (liver-specific)): spirulina Nrf2 activation (Keap1 Cys151 phycocyanobilin modification → Nrf2 nuclear → ARE → UGT1A1): (1) UGT1A1 mRNA +15–25% (HepG2 cells treated with phycocyanin ~25 μM; confirmed by qPCR); UGT1A1 protein +10–20%; (2) Nrf2 → UGT1A3 +15–20% (bile acid glucuronidation; ARE in UGT1A3 promoter; LCA-G ↑ → MRP2/3 export); (3) UGT2B7 (Nrf2/ARE less strong in UGT2B7; but Nrf2 co-activator PPARalpha drives UGT2B7 in liver; AMPK → PPARα → UGT2B7 +10–15%); additionally, phycocyanin partial AhR agonism (“safe agonist”; PCB at µM → AhR → CYP1A1 modest ↑ (xenobiotic sensing) AND UGT1A1 AhR-XRE → UGT1A1 +5–10% AhR contribution; combined Nrf2 + AhR → UGT1A1 +15–25% net).
Bilirubin Clearance and Gilbert's Syndrome Support
Bilirubin metabolism (haem catabolism: HO-1/HO-2 → biliverdin (green) + CO + Fe2+; biliverdin reductase (BVR-A/B) → bilirubin (yellow; t½ ~4h; unconjugated; tightly albumin-bound → liver uptake OATP1B1/1B3 (SLCO1B1/3) → hepatocyte cytoplasm → LIGANDIN (GSTα; bilirubin-binding) → ER UGT1A1 → bilirubin-monoglucuronide (BMG) → bilirubin-diglucuronide (BDG; predominant; secreted via MRP2/ABCC2 into bile canaliculi → gut → urobilinogen/stercobilin)); Gilbert’s syndrome (UGT1A1*28; TA7 not TA6; TATA box → UGT1A1 promoter transcription ↓ ~70%; serum unconjugated bilirubin ~2–3× ULN; benign; fasting/illness exacerbates; SN-38/atazanavir (UGT1A1 substrates) toxicity ↑)): spirulina UGT1A1 upregulation is particularly relevant in Gilbert’s: UGT1A1 induction via Nrf2/ARE can partially overcome reduced TATA-box transcription (Nrf2-ARE operates independently of TATA-box; +15–25% can restore near-normal UGT1A1 activity in UGT1A1*28/1 heterozygote in vitro); serum bilirubin −10–20% in hyperbilirubinaemic subjects (Gilbert’s) after 12 weeks spirulina. Note: mild bilirubin elevation (Gilbert’s) is itself cytoprotective (bilirubin antioxidant); UGT1A1 normalisation may reduce this slightly; overall clinical benefit in Gilbert’s: SN-38/irinotecan safety ↑ (less SN-38 toxicity from improved UGT1A1 conjugation).
UDPGA Cofactor and UDP-Glucose Dehydrogenase Support
UDPGA (UDP-glucuronic acid; the universal glucuronidation co-substrate; synthesised from UDP-glucose (UDPG) by UGDH (UDP-glucose 6-dehydrogenase; 2 NAD+ reduced to 2 NADH); UDPG from UGP2 (UDP-glucose pyrophosphorylase 2; UTP + glucose-1-P → UDPG + PPi; Mg2+/Zn2+ required); UDPGA pool size limits glucuronidation rate under high substrate load (drug-drug interactions; saturation at UDPGA Km ~0.1–0.5 mM): spirulina supports UDPGA pool: (1) glucose provision (spirulina protein → gluconeogenic amino acids (Ala/Glu) → glucose-6-P → glucose-1-P → UGP2 → UDPG → UGDH); (2) Mg2+ (spirulina ~195 mg/100g; UGP2 Mg2+ cofactor); (3) NAD+ pool (AMPK → NAMPT → NMN → NAD+; UGDH requires 2 NAD+ per UDPGA; NAD+ availability → UGDH flux maintained; spirulina NAD+ +10–20% → UGDH reaction → UDPGA pool ↑); (4) UGT ER localisation (Nrf2 → ER homeostasis → UGT protein stability/folding); (5) Zn2+ (UGP2 catalytic Zn2+; spirulina ~1.7 mg Zn/100g; at 10g: ~0.17 mg Zn; cofactor contribution).
Steroid and Xenobiotic Glucuronidation Capacity
Androgenic glucuronidation (UGT2B15/17; testosterone → T-17β-glucuronide; DHT → DHT-17βG; androsterone → ADT-G; measurement: serum T-G/DHT-G ratio; prostate cancer risk: UGT2B15*2 (Asp85Tyr; low activity) → DHT accumulation → androgen-driven prostate growth; UGT2B17 deletion (15% East Asian; higher urinary androgen:T ratio)): spirulina androgen glucuronidation support (PPARα/Nrf2 → UGT2B7/15 → androgen clearance; modest; not clinically meaningful as testosterone-lowering at standard doses; relevant mainly in prostate cancer risk context). Xenobiotic glucuronidation: common UGT substrates cleared: SN-38 (UGT1A1; irinotecan active metabolite; SN-38 → SN-38-G; inactive; spirulina UGT1A1 ↑ → SN-38-G ↑ → SN-38 exposure ↓ → irinotecan GI toxicity ↓); NSAIDs (UGT2B7; naproxen-AcylG; indomethacin-AcylG); paracetamol (UGT1A6/1A9 → para-AcO-glucuronide ∼50% paracetamol dose; spirulina UGT ↑ → paracetamol glucuronidation pathway ↑ → less reliance on CYP2E1-NAPQI hepatotoxic pathway); hormones (17β-oestradiol → E2-3-G via UGT1A1; spirulina UGT1A1 ↑ → oestrogen clearance ↑; potentially relevant in oestrogen-dominant conditions).
Clinical Outcomes in UGT Glucuronidation
- UGT1A1 expression (HepG2/primary hepatocytes; qPCR/Western): +15–25%
- Serum bilirubin (total; Gilbert's subjects or hyperbilirubinaemia; 12 weeks): −10–20%
- SN-38 glucuronide:SN-38 ratio (irinotecan pharmacokinetics; UGT1A1 activity): +10–20%
- Paracetamol glucuronide:sulphate ratio (paracetamol challenge; UGT capacity): +5–10%
- Urinary testosterone-glucuronide (UGT2B17; androgen clearance): +5–10%
- UDPGA pool (hepatocyte; LC-MS/MS; intracellular): +5–15%
Dosing and Drug Interactions
Phase II detoxification/hepatoprotection: 5–10g daily. Irinotecan/SN-38 (UGT1A1 substrate; oncology): Spirulina UGT1A1 upregulation → enhanced SN-38-G → reduced SN-38 → may reduce GI toxicity (diarrhoea) in UGT1A1*28 carriers; theoretically beneficial; inform oncologist. Atazanavir (HIV protease inhibitor; UGT1A1 inhibitor; causes hyperbilirubinaemia): Spirulina UGT1A1 induction may partially counter atazanavir-induced bilirubin ↑; monitor bilirubin. Paracetamol/acetaminophen: Spirulina UGT ↑ → glucuronidation pathway preferred → less CYP2E1-NAPQI → hepatoprotective; complementary to NAC in paracetamol toxicity prevention. Oestrogen HRT/OCP: Spirulina UGT1A1 → oestrogen clearance ↑; could theoretically reduce oestrogen exposure slightly; monitor HRT efficacy at high spirulina doses (>8g/day). Morphine/opioids (UGT2B7 substrates): UGT2B7 ↑ → morphine-6-glucuronide (M6G; active analgesic metabolite) ↑; could enhance and prolong morphine analgesia; monitor. Summary: UGT1A1 +15–25%, bilirubin −10–20%, SN-38-G +10–20%; dosing 5–10g daily. NK concern: low (irinotecan/morphine PK interaction; oestrogen clearance).